Chicago (ots/PRNewswire) - Brainlab releases an advanced version of the ExacTrac Patient Positioning system after more than one million frameless treatments Today, Brainlab officially unveils the new ExacTrac(R)6.0 Patient Positioning system, delivering key improvements for both frameless radiosurgery and ...
Geneva (ots/PRNewswire) - Alliance calls on governments to support the WHO strategy by setting regional targets to eradicate this killer disease The World Hepatitis Alliance have today welcomed the launch of the World Health Organization (WHO) framework for hepatitis as the global patient community marks World ...
Hatfield, England (ots/PRNewswire) - Eisai's new investigational molecule discovered and developed collaboratively in the UK and Japan Eisai in Europe today releases the first clinical data for E2609, a BACE (beta-site amyloid precursor protein-cleaving enzyme) inhibitor, presented during oral sessions at the ...
Hyderabad, India (ots/PRNewswire) - CPhI introduces Nano Suspensions India 2012 [http://ubmindia.co.in/cgi-bin18/DM/t/hzOj0dsj5Y0KYO0J7160EG ] which will be focusing on the most relevant and pressing issues around regulatory, QbD, solubility, stability and efficient scale-up of nano medicines. Taking place on 21-22 August 2012 at Fortune Select Manohar, Hyderabad, ...
Hoofddorp, Netherlands (ots/PRNewswire) - Nordic Group announced today that it has reached an agreement with Bayer HealthCare in which Nordic will acquire Trasylol(R) (aprotinin injection) worldwide excluding the United States. Under this agreement, Nordic will become the Marketing Authorization Holder for aprotinin in the relevant Territories. This follows the opinion ...
Zutphen, The Netherlands (ots/PRNewswire) - Cryo-Save Arabia's lab, located in Dubai, is now U.S. Food and Drug Administration (FDA) registered for autologous and family-related use of umbilical cord blood stem cells. This important accreditation confirms again the quality and high standards that are key to Cryo-Save. It is with great excitement that Cryo-Save Arabia, ...
Hatfield, England (ots/PRNewswire) - Metastatic breast cancer treatment Halaven(R) (eribulin) provides a statistically significant overall survival benefit for women with the disease Halaven(R) (eribulin), a novel treatment for patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease, has recently received registration approval from ...
Hatfield, England (ots/PRNewswire) - Reimbursement granted for Halaven(R) (eribulin) for women with locally advanced or metastatic breast cancer Halaven(R) (eribulin), a novel treatment for patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease, has today received reimbursement approval from the French health authorities. Prior ...
Hatfield, England (ots/PRNewswire) - Eisai Europe Limited today announces preliminary results from a recently completed Phase III study (Study 301) comparing Halaven(R) (eribulin) and Xeloda(R) (capecitabine). The study enrolled women with locally advanced or metastatic breast cancer in an earlier line of treatment ...
Zutphen, The Netherlands (ots/PRNewswire) - Free of charge, Cryo-Save's programme gives the opportunity to treat a family member diagnosed with a life-threatening disease treatable with stem cells. Cryo-Save, the leading international family stem cell bank, shows continuous commitment to its corporate social responsibility programme. Family and children's health is the company's number one priority. The Cryo-Save ...
http://resources.euroadhoc.com/us/HC3mrSSV issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard: ...
Shire Pharmaceuticals Group Plc
Nyon, Switzerland (ots/PRNewswire) - - In a head-to-head trial between VPRIV and Cerezyme(R) (imiglucerase), only patients treated with VPRIV experienced statistically significant improvement in lumbar spine bone mineral density at 9 months Shire plc , the global specialty biopharmaceutical company, today presented ...
http://resources.euroadhoc.com/us/19lpaarY issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: ...
Hatfield, England (ots/PRNewswire) - Zonegran(R) (zonisamide) set to offer new option for epilepsy treatment in Russia Eisai, one of the world's leading research-based pharmaceutical companies, announces the expansion of its operations into Russia, with the approval of its first product - the epilepsy treatment, Zonegran(R) (zonisamide). Eisai's entry into the Russian healthcare marketplace is part of the company's plan ...
http://resources.euroadhoc.com/us/RhIXs9ib company: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard: ...
Takeda Pharmaceutical Company Limited
Osaka, Japan And Bedminster, New Jersey (ots/PRNewswire) - - European CHMP adopts positive opinion for teduglutide (Revestive(R)) for patients with short bowel syndrome (SBS) - SBS is a rare and highly disabling condition that impacts patients' quality of life and can lead to serious life-threatening complications - ...
Bristol -Myers Squibb Company and Otsuka Pharmaceutical Co. Ltd
Paris (ots/PRNewswire) - Results Presented at 17th Congress of the European Hematology Association Bristol-Myers Squibb Company and Otsuka Pharmaceutical Europe Ltd., today announced results from the 3-year follow-up of the DASISION trial, which show that first-line treatment with SPRYCEL(R) 100 mg results infaster ...
Bristol-Myers Squibb & Otsuka Pharmaceutical Europe Ltd.
Paris (ots/PRNewswire) - Results Presented at 17th Congress of the European Hematology Association Bristol-Myers Squibb Company and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL(R) (dasatinib) in Philadelphia ...
Beerse, Belgium And Raritan, New Jersey (ots/PRNewswire) - ? Simultaneous Submissions Based on Data from Pre-chemo Prostate Cancer Study Janssen-Cilag International NV announced today it has submitted a type II variation to the European Medicines Agency (EMA) for ZYTIGA(R); simultaneously, Janssen Research & ...
http://resources.euroadhoc.com/us/oRuLxHhe issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: ...
Ballerup, Denmark (ots/PRNewswire) - LEO Pharma is now actively searching for new global or territorial partners to deliver promising new compounds for its dermatology-focused pipeline. Corporate VP hopes to sign two or more new deals before the end of 2012. (Logo: http://photos.prnewswire.com/prnh/20120614/537969-a ) (Photo: http://photos.prnewswire.com/prnh/20120614/537969-b ) (Photo: ...
Philadelphia (ots/PRNewswire) - Canagliflozin Provides Greater Reduction of A1C Levels in Adults with Type 2 Diabetes in 52-Week Head-to-Head Studies Compared to Sitagliptin and Glimepiride Janssen Research & Development, LLC (Janssen) presented results from five Phase 3 clinical studies evaluating canagliflozin in ...
Geneva, Switzerland (ots/PRNewswire) - Government Ignores Deteriorating Health of Federal Justice Workers In protest against repeated human and trade union rights violations, nine union members, five women and four men, began an unlimited hunger strike on 6 May in Algiers, Algeria. Despite urgent requests for meetings, and daily reports on the workers' rapidly ...
http://resources.euroadhoc.com/us/FuF7JANZ http://resources.euroadhoc.com/us/2dI7DlCg issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: ...
Uithoorn, The Netherlands (ots/PRNewswire) - Hoya appointed Mr. Donald Currie as the Managing Director of HOYA Hill Optics following the acquisition of 100% of the shares in the company. Managing Director and founder of Hill Optics, Mr. Clifford Sher, will resign on June 30th 2012, while Mr. Donald Currie, who until recently held the position of Managing Director at Carl Zeiss Vision joined HOYA Hill Optics from June 1st. ...
Frankfurt, Germany (ots/PRNewswire) - The categories and judging panel have been announced for the 7th edition of the Health ingredients, Natural ingredients & NuW awards programme, which recognizes exceptional innovations & talent within the nutrition + wellness industry. The focus of the health and wellness industry has switched gears. Instead of only taking an interest on health when a person's sick, consumers now seek ...
Bristol-Myers Squibb GmbH & Co. KGaA
Paris (ots/PRNewswire) - ? - ORENCIA demonstrated comparable efficacy to HUMIRA based on a non-inferiority endpoint for ACR20 response at 1 year - Kinetics of response for ACR20, 50 and 70, and inhibition of radiographic progression were generally comparable over 12 months - AMPLE is the first head-to-head study in ...
http://resources.euroadhoc.com/us/POjmfdPf issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: ...
issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard: ...
Jena, Germany (ots/PRNewswire) - Occlutech GmbH, the leading European developer of minimally invasive implants for the treatment of structural heart disease, today announced receiving a favourable Supreme Court ruling from The Hague in The Netherlands in the on-going patent litigation with AGA/St Jude Medical. A first instance court ruling obtained in favour of Occlutech had been appealed by AGA in 2008, as had the ...